Meta-Analysis Compared Overactive Bladder Medications
A 2026 study evaluated the efficacy and safety of vibegron, mirabegron, and tolterodine for patients.
Updated on Sept. 29, 2026 in Men’s Health
Live Poll
Do you trust your doctor's choice of medication over your own research into treatment options?
A 2026 systematic review and network meta-analysis compared the performance of three common overactive bladder medications. Researchers examined 5 trials involving 5,317 participants to determine which drug was most effective at reducing urinary symptoms.
Why it matters
The study was conducted because there has been a lack of adequately powered, direct randomized trials comparing these specific treatments. Findings help clarify clinical trade-offs between symptom relief and the frequency of side effects for patients managing these conditions.
A network meta-analysis of 5,317 participants across 5 trials compared 75 mg of vibegron, 50 mg of mirabegron, and 4 mg of tolterodine. Results showed vibegron ranked first for symptom improvement, though it had a 1.51 odds ratio for adverse events.
The players
NICE
The National Institute for Health and Care Excellence is a public body in the UK responsible for providing national guidance and advice to improve health and social care.
The details
Vibegron demonstrated the largest mean difference in reducing daily urinary urgency episodes and ranked first in improving maximum voided volume and urinary incontinence. While mirabegron showed the largest reduction in daily micturition frequency, it did not differ significantly from placebo regarding adverse event odds.
Timeline
2013: Mirabegron was introduced into UK treatment pathways.
2018: Vibegron received regulatory approval in Japan.
2024: NICE officially included vibegron in its overactive bladder pathway.
May 2025: The cutoff date for the literature search conducted by researchers.
2026: The study was published in a medical journal.
Health Landscape
This meta-analysis provides the comparative data necessary to update the clinical evidence base for NICE's overactive bladder treatment pathway. The findings help refine how these pharmaceutical interventions are positioned against each other in standardized care protocols.
Patients should discuss these comparative findings with their healthcare provider to weigh the benefits of increased symptom control against the potential for side effects. Individual treatment plans may shift as clinical guidelines incorporate this new evidence regarding drug efficacy.
The takeaway
Patients managing bladder urgency should consult with a physician to determine which medication best balances symptom relief with their personal tolerance for adverse events. Future clinical decisions for this condition will likely rely on these direct comparative performance rankings.
Further reading
Learn more about the latest developments in Men’s Health.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust your doctor's choice of medication over your own research into treatment options?
